What is the optimal imaging time for 99Tcm-(V)-DMSA planar scintigraphy in the detection of squamous carcinoma? A comparative study in humans and in an animal tumour model.
99Tcm-(V)-DMSA is a new tumour imaging agent which has been used to image squamous cell carcinoma (SCC) of the head and neck. There have been, however, no studies to date evaluating its optimal imaging time for SCC. Seven patients were studied (six SCC; one nontumour) and seven rabbits (six with SCC, (17 tumours); one nontumour). For the human qualitative studies there was a 67% sensitivity at 2, 4 and 6 h with image quality being optimum at 4 h. Maximum quantitative uptake occurred between 2 and 4 h. For the rabbit qualitative studies the optimum imaging time was 4 h (92% sensitivity, 100% specificity) and maximum quantitative uptake occurred at between 1.5 and 5 h. Taking into account the human and rabbit qualitative and quantitative studies combined with the pharmacokinetics and biodistribution of 99Tcm-(V)-DMSA, the optimum imaging time of 99Tcm-(V)-DMSA in humans with SCC was between 2 and 4 h.